Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18150694 | 0.89 | KMT2A (0.51) | KMT2AMEN1HCRTR2HCRTR1TP53 | |
| SCHEMBL9027766 | 0.84 | KMT2A (0.53) | KMT2AMEN1HCRTR2HCRTR1TP53 | |
| SCHEMBL9027753 | 0.84 | KMT2A (0.53) | KMT2AMEN1HCRTR2HCRTR1TP53 | |
| SCHEMBL9027772 | 0.84 | KMT2A (0.53) | KMT2AMEN1HCRTR2HCRTR1TP53 | |
| SCHEMBL18150553 | 0.82 | KMT2A (0.71) | KMT2AMEN1HCRTR2HCRTR1TP53 | |
| SCHEMBL16796874 | 0.81 | HCRTR2 (0.64) | KMT2AMEN1HCRTR2HCRTR1SIGMAR1 | |
| SCHEMBL18150752 | 0.80 | KMT2A (0.59) | KMT2AMEN1HCRTR2HCRTR1TP53 | |
| SCHEMBL18159810 | 0.79 | MEN1 (0.50) | KMT2AMEN1HCRTR2HCRTR1ALDH1A1 | |
| SCHEMBL9167755 | 0.78 | THRB (0.52) | KMT2AMEN1HCRTR2HCRTR1TP53 | |
| SCHEMBL9167742 | 0.78 | THRB (0.52) | KMT2AMEN1HCRTR2HCRTR1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266532-B2 | Tricyclic modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| EP-3288939-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | AbbVie Inc. (US) | 2018-03-07 | — | — | EP | disclosed |
| US-9856253-B2 | Tricyclic modulators of TNF signaling | ABBVIE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| WO-2016168641-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168641-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | KMT2A 4542/4885MEN1 2587/4885HCRTR2 1091/4885 |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | TNF, TNFRSF1A, CD40 | KMT2A 4542/4885MEN1 2587/4885HCRTR2 1091/4885 |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | KMT2A 4542/4885MEN1 2587/4885HCRTR2 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.